biotech / news / / Devdiscourse
The FDA has proposed removing popular weight-loss drugs from a key compounding list.
The FDA proposes removing semaglutide and tirzepatide from a key compounding list.
KEY POINTS
- Outsourcing facilities (503B) may face restrictions on producing these weight-loss drug compounds.
- Telehealth companies using 503A pharmacies, like Hims & Hers, are not directly impacted by the proposal.
- U.S.-listed shares of Novo Nordisk and Eli Lilly rose sharply following the FDA's announcement.
- The FDA will accept public comments on this proposal until June 29.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →